← Back to Screener
Vistagen Therapeutics, Inc. Common Stock (VTGN)
Price$0.61
Favorite Metrics
Price vs S&P 500 (26W)-93.17%
Price vs S&P 500 (4W)-6.42%
Market Capitalization$24.12M
All Metrics
Book Value / Share (Quarterly)$1.29
P/TBV (Annual)8.03x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-24.07%
Cash Flow / Share (Quarterly)$-1.53
Price vs S&P 500 (YTD)-9.31%
Net Profit Margin (TTM)-6634.91%
EPS (TTM)$-1.46
10-Day Avg Trading Volume0.68M
EPS Excl Extra (TTM)$-1.46
EPS (Annual)$-1.67
ROI (Annual)-73.05%
Net Profit Margin (5Y Avg)-4021.58%
Cash / Share (Quarterly)$1.56
Revenue Growth QoQ (YoY)29.49%
ROA (Last FY)-60.96%
Revenue Growth TTM (YoY)15.28%
EBITD / Share (TTM)$-1.51
ROE (5Y Avg)-136.34%
Operating Margin (TTM)-6882.36%
Cash Flow / Share (Annual)$-1.46
P/B Ratio0.47x
P/B Ratio (Quarterly)0.51x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)-28.42x
Net Interest Coverage (TTM)-2458.00x
ROA (TTM)-74.56%
EPS Incl Extra (Annual)$-1.67
Current Ratio (Annual)6.51x
Quick Ratio (Quarterly)4.57x
3-Month Avg Trading Volume2.05M
52-Week Price Return-69.68%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.97
P/S Ratio (Annual)49.62x
Asset Turnover (Annual)0.01x
52-Week High$5.14
Operating Margin (5Y Avg)-4278.00%
EPS Excl Extra (Annual)$-1.67
Tangible BV CAGR (5Y)11.80%
26-Week Price Return-84.42%
Quick Ratio (Annual)6.38x
13-Week Price Return-10.52%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)4.67x
Enterprise Value$-22.875
Asset Turnover (TTM)0.01x
Book Value / Share Growth (5Y)-13.70%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-10578.40%
Cash / Share (Annual)$2.78
3-Month Return Std Dev68.08%
Net Income / Employee (TTM)$-1
ROE (Last FY)-73.05%
Net Interest Coverage (Annual)-5.41x
EPS Basic Excl Extra (Annual)$-1.67
Receivables Turnover (TTM)4.00x
Total Debt / Equity (Quarterly)0.01x
EPS Incl Extra (TTM)$-1.46
ROI (TTM)-91.04%
P/S Ratio (TTM)29.96x
Pretax Margin (5Y Avg)-4021.05%
Revenue / Share (Annual)$0.02
Tangible BV / Share (Annual)$1.65
Price vs S&P 500 (52W)-104.77%
Year-to-Date Return-5.17%
5-Day Price Return8.98%
EPS Normalized (Annual)$-1.67
ROA (5Y Avg)-89.22%
Net Profit Margin (Annual)-10579.84%
Month-to-Date Return9.83%
Cash Flow / Share (TTM)$-4.52
EBITD / Share (Annual)$-1.81
Operating Margin (Annual)-11517.08%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-135.54%
LT Debt / Equity (Quarterly)0.02x
EPS Basic Excl Extra (TTM)$-1.46
P/TBV (Quarterly)2.72x
P/B Ratio (Annual)1.03x
Pretax Margin (TTM)-6634.91%
Book Value / Share (Annual)$2.43
Price vs S&P 500 (13W)-13.39%
Beta0.39x
Revenue / Share (TTM)$0.02
ROE (TTM)-92.08%
52-Week Low$0.43
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
2.50
2.50
2.50
2.50
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
VTGNVistagen Therapeutics, Inc. Common Stock | 29.96x | 15.28% | — | — | $0.61 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Vistagen Therapeutics is a biotechnology company developing novel therapies for psychiatric and neurological disorders using proprietary nose-to-brain delivery technology. The company's targeted approach leverages neurocircuitry insights to potentially create unique treatment pathways for conditions currently lacking effective options.